Long-term treatment with 'Duovent' in elderly patients affected by chronic obstructive lung disease. 1986

L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto

Twelve patients, aged over 60 years and suffering from chronic obstructive lung disease, were treated for 12 weeks with Duovent (fenoterol + ipratropium bromide). The clinical check-ups and indices of bronchial obstruction (FEV1, VC, RV, sGaw) were performed every 14 days. Improvement in symptoms corresponded to a significant improvement in the functional parameters. No negative cardiovascular effects, significant side-effects, or tolerance were seen after drug administration.

UI MeSH Term Description Entries
D008173 Lung Diseases, Obstructive Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent. Obstructive Lung Diseases,Obstructive Pulmonary Diseases,Lung Disease, Obstructive,Obstructive Lung Disease,Obstructive Pulmonary Disease,Pulmonary Disease, Obstructive,Pulmonary Diseases, Obstructive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009241 Ipratropium A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. N-Isopropylatropine,(endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane,Atrovent,Ipratropium Bromide,Ipratropium Bromide Anhydrous,Ipratropium Bromide Monohydrate,Ipratropium Bromide, (endo,anti)-Isomer,Ipratropium Bromide, (exo,syn)-Isomer,Ipratropium Bromide, endo-Isomer,Itrop,Sch-1000,Sch-1178,N Isopropylatropine,Sch 1000,Sch 1178,Sch1000,Sch1178
D012115 Residual Volume The volume of air remaining in the LUNGS at the end of a maximal expiration. Common abbreviation is RV. Residual Volumes,Volume, Residual,Volumes, Residual
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D005280 Fenoterol A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic. Berotec,Berotek,Fenoterol Hydrobromide,Fenoterol Hydrochloride,Partusisten,Phenoterol,Th-1165a,p-Hydroxyphenyl-orciprenaline,p-Hydroxyphenylorciprenaline,Hydrochloride, Fenoterol,Th 1165a,Th1165a,p Hydroxyphenyl orciprenaline,p Hydroxyphenylorciprenaline

Related Publications

L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
September 1987, Ugeskrift for laeger,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
February 1974, Vnitrni lekarstvi,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
December 2021, Zhonghua yi xue za zhi,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
March 2005, Central European journal of public health,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
May 1986, European journal of respiratory diseases,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
September 1985, British journal of clinical pharmacology,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
January 1983, Respiration; international review of thoracic diseases,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
January 1978, Respiration; international review of thoracic diseases,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
August 1988, The European respiratory journal,
L Cecere, and G Funaro, and G De Cataldis, and P Carnicelli, and R Pinto
September 2006, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
Copied contents to your clipboard!